Highlights ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Delayed Nasdaq Stockholm Other stock markets 03:32:21 2024-04-30 am EDT			5-day change	1st Jan Change
2.55 ^SEK	-1.92%		-16.03%	+19.19%

Apr. 16	ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	CI
Feb. 21	ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	Apr. 16	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
Evaxion Biotech Teams Up With ExpreS2ion Biotechnologies for Vaccine Candidate Development	22-12-06	MT
ExpreS2ion, Evaxion Team Up to Develop New Cytomegalovirus Vaccine	22-12-06	MT
ExpreS2ion and Evaxion Biotech A/S Initiates Research Collaboration on a Novel Cytomegalovirus Vaccine Candidate	22-12-06	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Expres2ion Biotech Holding AB Announces Durable Antibody Response Reported for the Abncov2 Covid-19 Vaccine Six Months After Vaccination in the Phase Ii Clinical Trial	22-10-17	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-31	CI
Expres2ion Biotech Holding AB Announces Positive Omicron Data from the Covid-19 Phase Ii Trial Reported for the Abncov2 Vaccine	22-05-05	CI
Expres2ion Biotech Holding AB Provides Additional Positive Phase II Covid-19 Results Presented for the Abncov2 Vaccine	22-02-28	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Expres2ion Biotech Holding AB Announces Further Efficacy Data from the Covid-19 Clinical Phase I/Ii Study with Abncov2 Confirms Strong Positive Results	21-11-12	CI
ExpreS2ion Biotechnologies Announces Exclusive Licensee of the ABNCoV2 COVID-19 vaccine	21-08-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Highlights

Filters